| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | SEARCH RESULT |
|
|
|
||||||||
|
||||||||||
|
|
|||||||||
|
|
Departments of Nuclear Medicine and Radiotherapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; Department of Nuclear Medicine, Gunma University School of Medicine, Maebashi, Japan; Department of Nuclear Medicine, Hospital Clinic de Barcelona, University School of Medicine, Barcelona, Spain
Correspondence: For correspondence or reprints contact: E. Edmund Kim, MD, Department of Nuclear Medicine, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030.
ABSTRACT
We investigated the diagnostic accuracy of FDG-PET in the detection of recurrent lung cancer. Methods: Thirty-nine lesions in 38 patients with clinically suspected recurrent or residual lung cancer were studied with PET. All PET images were visually interpreted in conjunction with thoracic CT or MRI. Semiquantitative analysis using standardized uptake values (SUVs) was also performed in 25 lesions. FDG-PET diagnoses were correlated with pathological diagnoses and clinical outcome. Results: The sensitivity and specificity of FDG-PET for detecting recurrent tumors were 100% (26/26) and 61.5% (8/13), respectively. The difference in mean SUV between recurrent tumors and noncancerous lesions was statistically significant [11.2 ± 5.7 (n = 16) vs. 3.5 ± 1.8 (n = 9), p <0.0001]. False-positive results showed relatively lower SUVs than true-positives and also demonstrated increased uptake in a curvilinea rather than nodular shape. Conclusion: FDG-PET is useful for detecting recurrent lung cancer after treatment. False-positive diagnoses might be reduced by analysis of uptake shape and serial changes in SUV, but further study is needed.
Key Words: positron emission tomography • fluorodeoxyglucose • lung cancer • recurrent lung cancer
This article has been cited by other articles:
|
|
 |
|
  S. Cho and E. B. Lee A follow-up of integrated positron emission tomography/computed tomography after curative resection of non-small-cell lung cancer in asymptomatic patients J. Thorac. Cardiovasc. Surg., June 1, 2010; 139(6): 1447 - 1451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Kanzaki, M. Higashiyama, J. Maeda, J. Okami, T. Hosoki, Y. Hasegawa, M. Takami, and K. Kodama Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients Interactive CardioVascular and Thoracic Surgery, June 1, 2010; 10(6): 1009 - 1014. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nakamura, S. Hatooka, T. Kodaira, H. Tachibana, N. Tomita, R. Nakahara, H. Inokuchi, N. Mizoguchi, A. Takada, M. Shinoda, et al. Determination of the Irradiation Field for Clinical T1-T3N0M0 Thoracic/Abdominal Esophageal Cancer Based on the Postoperative Pathological Results Jpn. J. Clin. Oncol., February 1, 2009; 39(2): 86 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rubins, M. Unger, and G. L. Colice Follow-up and Surveillance of the Lung Cancer Patient Following Curative Intent Therapy: ACCP Evidence-Based Clinical Practice Guideline (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 355S - 367S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Juweid and B. D. Cheson Positron-Emission Tomography and Assessment of Cancer Therapy N. Engl. J. Med., February 2, 2006; 354(5): 496 - 507. [Full Text] [PDF]
|
|
|
|
 |
|
 L. K. Shankar and D. C. Sullivan Functional Imaging in Lung Cancer J. Clin. Oncol., May 10, 2005; 23(14): 3203 - 3211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Keidar, N. Haim, L. Guralnik, M. Wollner, R. Bar-Shalom, A. Ben-Nun, and O. Israel PET/CT Using 18F-FDG in Suspected Lung Cancer Recurrence: Diagnostic Value and Impact on Patient Management J. Nucl. Med., October 1, 2004; 45(10): 1640 - 1646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. E. Erdi, S. A. Nehmeh, T. Pan, A. Pevsner, K. E. Rosenzweig, G. Mageras, E. D. Yorke, H. Schoder, W. Hsiao, O. D. Squire, et al. The CT Motion Quantitation of Lung Lesions and Its Impact on PET-Measured SUVs J. Nucl. Med., August 1, 2004; 45(8): 1287 - 1292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. W. Choi, R. F. Munden, J. J. Erasmus, K. Joo Park, W. K. Chung, S. C. Jeon, and C.-K. Park Effects of Radiation Therapy on the Lung: Radiologic Appearances and Differential Diagnosis RadioGraphics, July 1, 2004; 24(4): 985 - 997. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Aoki, Y. Nagata, Y. Negoro, K. Takayama, T. Mizowaki, M. Kokubo, N. Oya, M. Mitsumori, and M. Hiraoka Evaluation of Lung Injury after Three-dimensional Conformal Stereotactic Radiation Therapy for Solitary Lung Tumors: CT Appearance Radiology, January 1, 2004; 230(1): 101 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Colice, J. Rubins, and M. Unger Follow-up and Surveillance of the Lung Cancer Patient Following Curative-Intent Therapy Chest, January 1, 2003; 123 (2009): 272S - 283S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. A. Nabi and J. M. Zubeldia Clinical Applications of 18F-FDG in Oncology J. Nucl. Med. Technol., March 1, 2002; 30(1): 3 - 9. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Hicks, V. Kalff, M. P. MacManus, R. E. Ware, A. F. McKenzie, J. P. Matthews, and D. L. Ball The Utility of 18F-FDG PET for Suspected Recurrent Non-Small Cell Lung Cancer After Potentially Curative Therapy: Impact on Management and Prognostic Stratification J. Nucl. Med., November 1, 2001; 42(11): 1605 - 1613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Komaki, M. H. Chasen, W. D. Travis, J. B. Putnam, F. V. Fossella, R. W. Byhardt, and J. Y. Ro Oncodiagnosis Panel: 1999: Cancer of the Lung: Oncodiagnosis RadioGraphics, November 1, 2001; 21(6): 1573 - 1596. [Full Text] [PDF]
|
|
|
|
|
|
T. Kawamura, Y. Sando, S. Tajima, T. Hosono, M. Sato, Y. Maeno, T. Maeno, T. Suga, M. Kurabayashi, and R. Nagai Pulmonary Intravascular Lymphoma Complicated with Pneumocystis Carinii Pneumonia: a Case Report Jpn. J. Clin. Oncol., July 1, 2001; 31(7): 333 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Inoue, K. Koyama, N. Oriuchi, S. Alyafei, Z. Yuan, H. Suzuki, K. Takeuchi, Y. Tomaru, K. Tomiyoshi, J. Aoki, et al. Detection of Malignant Tumors: Whole-Body PET with Fluorine 18 {{alpha}}-Methyl Tyrosine versus FDG—Preliminary Study Radiology, July 1, 2001; 220(1): 54 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Aoki, H. Watanabe, T. Shinozaki, K. Takagishi, H. Ishijima, N. Oya, N. Sato, T. Inoue, and K. Endo FDG PET of Primary Benign and Malignant Bone Tumors: Standardized Uptake Value in 52 Lesions Radiology, June 1, 2001; 219(3): 774 - 777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Gambhir, J. Czernin, J. Schwimmer, D. H. S. Silverman, R. E. Coleman, and M. E. Phelps A Tabulated Summary of the FDG PET Literature J. Nucl. Med., May 1, 2001; 42(90050): 1S - 93. [Full Text] [PDF]
|
|
|
|
 |
|
 J.F. Vansteenkiste and S.G. Stroobants The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology Eur. Respir. J., April 1, 2001; 17(4): 802 - 820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. D. Maki, W. B. Gefter, and A. Alavi Recent Advances in Pulmonary Imaging Chest, November 1, 1999; 116(5): 1388 - 1402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. J Lowe and K. S Naunheim Current role of positron emission tomography in thoracic oncology Thorax, August 1, 1998; 53(8): 703 - 712. [Full Text]
|
|
|
|
 |
|
 V. J. Lowe and K. S. Naunheim Positron Emission Tomography in Lung Cancer Ann. Thorac. Surg., June 1, 1998; 65(6): 1821 - 1829. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | SEARCH RESULT |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
